

PATENT SPECIFICATION

(11) 1 473 148

1 473 148

- (21) Application No. 40175/74 (22) Filed 16 Sept. 1974
 (44) Complete Specification published 11 May 1977
 (51) INT CL² C07D 239/52; A61K 31/505, 31/675; C07D 239/22,
 405/04, 493/02; C07H 5/04, 11/04 (C07D 405/04,
 239/52) (C07D 493/02, 239/22, 307/20, 317/18)

(52) Index at acceptance

C2C 1472 1504 1600 1601 1602 1603 214 215 220 22Y 247
 250 252 253 25Y 28X 292 29Y 30Y 311 313 314 315
 31Y 337 351 352 360 361 362 365 366 368 36Y 386
 387 388 389 623 625 628 633 635 643 648 652 658
 65X 668 672 678 679 67X 698 699 761 762 764 766
 774 777 790 79Y BK TL TM TR WK

(19)



(54) PLATINUM-DIOXOPYRIMIDINE COMPLEXES

(71) We, RESEARCH CORPORATION, a Corporation of the State of New York, United States of America, having a place of business at 405 Lexington Avenue, New York, State of New York, United States of America, do hereby declare the invention, for which we pray that a patent may be granted to us, and the method by which it is to be performed, to be particularly described in and by the following statement:—

Our earlier researches have shown that various platinum coordination compounds for example malonato-platinum compounds, are useful as anti-tumor agents and in the treatment of viral conditions. These platinum coordination compounds suffer from the disadvantages of (1) having a high level of renal toxicity, and (2) a low solubility in water. The latter characteristic renders the preparation of therapeutically useful compositions difficult.

It has now been discovered that a certain class of platinum "blue" complexes have a high anti-tumor activity, are soluble in water, and have a low level of renal toxicity.

The prior art has long been aware of the so-called "platinblau" complexes. Credit for the discovery of "Platinblau", as these blue complexes were designated, is usually given to Hofmann and Bugge (Ber. 41: 312—314, 1908). They reacted Ag_2SO_4 with the yellow platinum (II) coordination compound,



in aqueous solution and isolated a deep blue, amorphous material. It was thought to be monomeric in nature, containing platinum in the divalent state. Since this discovery only a few papers have appeared concerning further studies on "Platinblau" and similar blue products. Gillard and Wilkinson (J. Chem. Soc., 2835—37, 1964) postulated that "Platinblau" had the empirical formula



with polymeric chains, bridging acetamide groups, and divalent platinum. Brown et al

(J.A.C.S. 91:11: 2895—2902, 1969 and 90:20: 5621—5622, 1968) have attempted to demonstrate that it is a platinum (IV) complex containing chelating acetamide ligands, and hydroxyl groups in the other two coordination positions. We have found that both blue and purple products could be isolated from the "Platinblau" reaction, with the purple species being the more highly oxidized (*vide infra*). Thus, there is considerable controversy over the exact nature of this complex. Brown et al (*ibid.*) have also reported the preparation of highly colored amide complexes of platinum by heating, for example, trimethylacetamide and either $\text{Pt}(\text{CH}_3\text{CN})_2\text{Cl}_2$ or $\text{K}_2[\text{PtCl}_4]$ (a reddish colored salt). From this reaction three components were identified by chromatography. These were two yellow crystalline materials and a blue amorphous powder. Although they reported that they could not identify any of these products in a positive manner, they postulated that the blue material contained tetravalent platinum, with bidentate amide anions and chloride ligands completing the coordination sphere.

The only other reference to anomalously colored platinum compounds containing *cis*-amino groups as ligands rather than amides is that concerning mixtures of *cis*-dichlorodiammineplatinum (II) and sulfuric acid (Gillard et al, *ibid.*). Crystals of this blue black material were obtained and a preliminary X-ray diffraction study showed that the Pt—Pt distance was 3.06 Å, suggesting strong interaction. They concluded that this complex contained layers of *cis*-dichlorodiammineplatinum (II) held together by Pt—Pt bonds, with the sulfate ion hydrogen bonded to the coordinated ammonia groups.

The present invention is predicated on the discovery that the "platinum blue" complexes formed by the reaction of *cis*-diaquodiammineplatinum II with a 2,4-dioxypyrimidine are anti-tumor, anti-viral and anti-bacterial agents with a low level of renal toxicity and a high

50

55

60

65

70

75


80

85

90

degree of solubility in water.

Suitable 2,4-dioxypyrimidines include those having the formula:



5 wherein:

R_1 and R_2 may be the same or different and are selected from H, lower alkyl, di-lower alkyl amino, di-halo lower alkyl amino, halogen, hydroxy, hydroxy lower alkyl and carbonyl-loweralkoxy,

10 R_3 and R_4 may be the same or different and are selected from H, lower alkyl ribosyl, deoxyribosyl, triacetyl, tribenzoyl or 2', 3'-loweralkylidene ribosyl, ribosyl, ribosyl phosphates and deoxyribosyl phosphates,

15 or the 5,6-dihydro derivatives thereof.

In this specification, the terms "lower alkyl", "lower alkoxy" and "lower alkylidene" respectively mean an alkyl, alkoxy and alkylidene group having six or fewer carbon atoms.

20 The invention also relates to a method for preparing the platinum-[2,4-dioxypyrimidine] complexes by reacting the above-described 2,4-dioxypyrimidines with *cis*-diaquodiammineplatinum (II) wherein the molar ratio of pyrimidine to platinum compound is from 2:1 to 1:1 at a temperature of from 0 to 55°C., and for a time sufficient to form the complex.

25 The invention also relates to a pharmaceutical composition adapted for the treatment of tumors, bacterial and viral infections and arthritic conditions comprising, in dosage unit form, a pharmaceutically acceptable carrier and from 0.1 mg/ml to 50 mg/ml of a complex of 2,4-dioxypyrimidine and platinum compound as described above.

30 The present invention also relates to a method for the treatment of tumors and bacterial and viral infections comprising the administration to a non-human living being afflicted with the malady from 1 mg/kg to 800 mg/kg of body weight of the above-described complex.

35 Although the complexes of the invention are referred to as "platinum blue" complexes for purposes of convenience, the products of some of the above-described reactions are in reality mixtures which are extremely difficult to separate. Analysis and molecular weight determinations have enabled certain conclusions to be drawn.

40 Generally, the complexes contain one pyrimidine molecule per molecule of platinum. For the most part, each complex contains two ammonia ligands, one pyrimidine anion and one hydroxide ion per platinum molecule, but with two additional oxygen atoms at an un-

specifiable location. The 5-fluorouracil complex is an exception in that it does not contain excess oxygen.

The *cis*-diammino configuration of platinum appears to be essential for forming the complexes of the invention.

60 Although the 2,4-dioxypyrimidine moiety of the platinum complex may be variously substituted in the 1,3,5, and 6 positions as set forth above, the preferred complexes are those wherein R_1 , R_2 , R_3 and R_4 are each hydrogen and wherein R_1 , R_3 and R_4 are each hydrogen and R_2 is CH_3 . These compounds are uracil and thymine. The complexes formed by the reaction of uracil and thymine with *cis*-diaquodiammineplatinum (II) have been found to be especially effective anti-tumor, anti-bacterial and anti-viral agents.

70 As noted above, the exact structure of these complexes is at present unknown. They are, however, extremely soluble in water. They may be prepared by reacting the appropriate 2,4-dioxypyrimidine with *cis*-diaquodiammineplatinum (II) in an aqueous solution wherein the molar ratio of 2,4-dioxypyrimidine to the platinum complex is from 2:1 to 1:1 at a temperature in the range of from 0 to 55°C., preferably at room temperature, for a time sufficient for the complex to form, preferably from 1 to 21 days. The method is preferably carried out in an aqueous medium wherein the pH ranges from 3 to 8, preferably about 6.5.

80 The most notable characteristic of the compounds of the invention is their extreme solubility in water, i.e., of the order of 1 g per 10 ml of water. Their extreme solubility renders them particularly adapted for the treatment of tumors and bacterial and viral infections in living beings.

90 For example, the *cis*-diaquodiammineplatinum(II)-uracil complex was found to be particularly effective against the ascites Sarcoma-180 tumor in the Swiss white mouse. The toxicity of the complex was extremely low and the mice tolerated up to 500 mg per kg of body weight as a single dose injection of the complex without any deaths.

95 The complex described above was also found to be effective against the Fowl Pox virus when incubated therewith for extremely short periods of time prior to inoculation into an embryonated egg as a system. It was also found that the complex could be injected into the egg well after the inoculation with the virus and still prevent development of the pox formation typical of a live virus attack upon the membrane.

100 As another example of the diversified activity of the platinum-uracil complex, it was tested against *E. coli* growing in test tube cultures. Even at very low concentrations, i.e., 5 ppm, the bacteria formed clumps and did not show filamentation. At higher concentrations, i.e., greater than 40 ppm, the bacteria were completely killed.

60

65

70

75

80

85

90

95

100

105

110

120

125

The platinum-uracil complex has also been found to be effective against the ADJ/PC6 tumor system.

5 The complexes of the invention may be compounded with conventional pharmaceutical carriers in the preparation of pharmaceutical compositions for the treatment of tumors, bacterial and viral infections. The compositions should comprise, in dosage unit
10 form, a pharmaceutically acceptable carrier and from 0.1 mg/ml to 50 mg/ml of the above-described complex.

15 The mode of administration of the platinum-uracil and related complexes will depend upon the particular malady to be treated. Solutions may be administered by injection via the intraperitoneal, intramuscular, subcutaneous or intravenous routes, or as a solid, per os.

20 The invention is illustrated by the following non-limiting Examples:

EXAMPLE 1.

3 grams of *cis*-dichlorodiammineplatinum (II) (0.01 moles) and .02 moles of silver nitrate in 100 ml of water were stirred overnight at 23°C. in the dark. The silver removes the chlorides from the platinum complex and produces 100% yields of the *cis*-diaquodiammineplatinum (II). The silver chloride is then filtered off. It is necessary to remove all of the silver ions from solution. A small aliquot of the remaining solution is tested for excess silver by adding a small amount of 0.1 molar HCl. If the solution turns cloudy the reaction has not yet proceeded to completion. When
35 the solution remains clear, the reaction is considered complete. The solution is then neutralized with 2.0 normal sodium hydroxide to yield a final pH value of between 6 and 7. Then, 1.12 grams of uracil is dissolved in 100
40 milliliters of water to form a slurry. The pH is then adjusted to 9 with 2.0 normal sodium hydroxide and warmed to 50°C to dissolve the uracil to give a solution containing .01 moles of uracil. The uracil solution is then mixed
45 with the *cis*-diaquodiammineplatinum(II) complex to provide a 1 to 1 ratio on a molecular basis of the two reactants. The pH is adjusted to between 6 and 7. The vessel is stoppered, covered with aluminum foil, and
50 placed in a water bath at 37°C for a period of one week to complete the reaction. A blue color

forms after approximately 24 hours. After one week there is a small amount of blue precipitate. The solution is cooled to near 0° overnight and a large amount of a blue precipitate forms. This is filtered, and washed with a very small amount of cold water. The filtrate is washed three times with large amounts (approximately 150 milliliters each time) of 200 proof, boiling ethanol to remove excess uracil that may be present. After the third wash the ethanol when cooled should remain clear, indicating no further free uracil in solution. The filtrate is air dried, then vacuum dried for 12 hours at 40°C. The result is a dark blue, powdery, pure sample of the Platinum-Uracil complex.

The supernatant liquid from the initial filtration was evaporated to about 25% of its original volume and an equal volume of ethanol was added. Cooling to 0°C. gave more blue precipitate and a dark-green solution. The blue precipitate was filtered and the filtrate further concentrated. The addition of more ethanol gave a pale-green precipitate.

Obviously, therefore, the method of the invention yields a complex mixture of "platinum blue" compounds. It is to be understood, however, that the invention includes all of the diverse components of the reaction mixture, whether in admixture or in isolated form.

Generally, the first derived precipitate, i.e., the blue precipitates are less soluble in water-ethanol mixtures. The second derived component is more soluble in water-ethanol.

Example 2.

The procedure of Example 1 was followed utilizing 2', 3', 5'-triacetyluridine except that the solution was evaporated to dryness and the complex dissolved in ethanol. Addition of ether gave a dark-blue hygroscopic precipitate which was collected and washed with ether.

Examples 3—13.

The procedure of Example 1 was followed in preparing the complexes set forth in Table 1. The Elemental Analyses of the complexes of Examples 1 and 3—14 are also set forth in Table 1. The compounds obtained at the first precipitation are referred to as "Class IA" compounds; those obtained at the second precipitation are referred to as "Class IB" compounds.

TABLE I
Elemental Analyses of Complexes

Compound	% C	% H	% N	% O	% Cl	% F	% Pt	M W
C.I. ASS 1A ("blue or 1st precipitate")								
uracil (Ex. 1)	12.31	2.49	14.55	20.65	—	—	50.00*	805
thymine (Ex. 3)	14.05	3.26	15.65	18.97	—	—	48.07*	—
5,6-dihydro-6-methyluracil (Ex. 4)	13.07	3.36	15.60	17.21	—	—	50.76*	—
5,6-dihydrothymine (Ex. 5)	11.65	2.69	13.29	10.55	—	—	61.82*	283
1-methyluracil (Ex. 6)	14.65	2.63	14.08	19.77	—	—	48.87*	—
5,6-dimethyluracil (Ex. 7)	16.96	3.38	15.07	15.78	—	—	48.81*	—
5-carbethoxyuracil (Ex. 8)	17.94	3.07	13.91	15.86	—	—	49.22*	—
5-chlorouracil (Ex. 9)	10.16	2.17	14.91	17.98	8.76	—	46.02*	—
6-chlorouracil (Ex. 10)	11.24	2.45	13.37	18.63	8.28	—	46.03*	433
5-hydroxymethyluracil (Ex. 11)	12.25	2.68	14.47	20.48	—	—	50.12*	379

TABLE I (Continued)

Compound	% C	% H	% N	% O	% Cl	% F	% Pt	M W
CLASS IB ("green" or 2nd precipitate)								
uracil (Ex. 1)	11.68	2.59	14.23	23.95	—	—	47.55*	—
thymine (Ex. 3)	14.55	3.20	15.45	19.63	—	—	47.17*	388
1-methylthymine (Ex. 12)	16.17	3.05	15.53	17.81	—	—	47.44*	371
CLASS IA ("blue")								
5-fluorouracil (Ex. 13)								
calc. for $\text{PtC}_4\text{H}_6\text{N}_4\text{O}_3\text{F}$	12.80	2.42	14.93	—	—	5.06	—	375
found	12.65	2.26	14.75	—	—	5.09	—	381
CLASS IB ("green")								
5-fluorouracil (Ex. 13)								
calc. for $\text{PtC}_4\text{H}_6\text{N}_4\text{O}_3\text{F}$	12.80	2.42	14.93	—	—	5.06	—	375
found	13.05	2.36	15.09	—	—	5.17	—	374

* calculated by difference.

Some of the "platinum blue" complexes of the invention are believed to be mixtures of oligomeric species including monomers, dimers and trimers.

5 It is, for this reason, difficult to interpret the infrared spectra of the complexes with regard to structural features. They are characterized by the fact that they have an absorption band in the visible red region, consisting
10 either of a single or a double peak which imparts the characteristic green, blue or violet color to the various complexes. An absorption spectrum of the *cis*-diaquodiammineplatinum (II)-uracil complex as prepared above is
15 shown in the accompanying drawing. It can be assumed from the infrared spectra that the ammine ligands are present and that a ring structure still exists. While possessing high solubilities in water, the complexes have
20 very limited solubilities in solvents such as dimethylformamide and dimethylsulfoxide.

X-ray diffraction and electron diffraction analyses of the platinum-uracil complex show a completely amorphous material.

25 Conductivity tests suggest that the complexes are neutral species.

The visible spectra of a number of different samples of the platinum-uracil complexes were measured on a Cary 15 Spectrophotometer in aqueous solution in 1 cm quartz cells at concentrations of 10 mg/10 ml (1 mg/ml). For
30 a sample which analyzed to have a M.W. = 1200 the spectrum contained a broad band centered at 722 nm with adsorbance $\cong 0.9$ and a broad shoulder at 582 nm (O.D. = 0.74). A
35 sample believed to be a monomeric species (m.w. $\cong 400$) had a broad shoulder at 617 nm (O.D. = 0.6), a broad band at 563 nm (O.D. = 0.62) and a band at 468 nm (O.D. = 0.42).

40 The proton magnetic resonance spectra of the platinum-uracil, thymine and 5,6-dimethyluracil complexes samples were recorded in a Varian A56/60 Spectrometer in D₂O solution using DSS (a water soluble form of
45 TMS) as internal reference (set to 0 ppm). The platinum-uracil complex exhibited a sharp doublet centered at 2.84 ppm (peaks at 2.76 and 2.92 ppm), a peak due to the solvent at 4.47 ppm and a weak broad (1 ppm width
50 at half height) at 7.69 ppm. For the Pt-Thymine complex, with the solvent peak adjusted to 4.47 ppm, the spectrum showed a broad (2 ppm width at half height) peak at 1.71 ppm, a sharp doublet centered at 2.85
55 ppm (peaks at 2.77 and 2.93 ppm) and a weak broad peak (1 ppm wide) at 7.5 ppm (possibly due to unreacted free base). Free uridine in D₂O gives pmr spectrum with a doublet assigned to the uracil H₆ protons at 7.65 ppm
60 and a doublet due to the H₅ protons at 5.80 ppm (solvent peak 4.54 and DDS at 0 ppm). Free thymine in d₆-DMF solutions has a sharp peak at 1.72 ppm assigned to methyl protons and a broad weak peak at 7.20 ppm
65 (assigned to H₆) with TMS set at 0 ppm.

The spectrum of the 5,6-dimethyluracil compound contained peaks at 1.76 and 2.07 ppm relative to HDO at 4.47 ppm. From these spectra we can only conclude that the magnetic environment of the protons in the bases
5 changes when they become coordinated in these blue complexes to increase the shielding of the protons.

The electron scattering for chemical analysis (ESCA) measurements on the binding energy of the 4f electrons in a platinum from X-ray Photoelectron Spectroscopy yields a value for
10 *cis*-Pt(NH₃)₂Cl₂ of 73.02 eV. The platinum in the platinum-uracil complex gave a value of 73.6 eV. This suggests that the valence state of platinum in the platinum-uracil is II and not IV.

The electronic absorption spectra of the blue precipitate of the platinum-uracil complex contain broad absorption bands in the vicinity of 550—650 nm with molar extinction coefficients on the order of 500—1000
20 l mole⁻¹ cm⁻¹. The green precipitate fraction of the platinum uracil complex contains a single broad band near 720 nm of similar intensity. These blue and green compounds contain a very intense band near 290 nm.

The chemotherapeutic activities of the "Platinum Blue" complexes were determined using the ascites Sarcoma-180 tumor in Swiss
30 White mice. The protocols for these tests were as follows: Random bred female Swiss White mice (Spartan Laboratory, Williamston, Michigan) of 18—20 grams weight were randomized in groups of six. The ascites cells
35 were removed from the peritoneal cavities of animals with approximately 10 day old ascites tumors. The cells were washed several times with 0.85% saline and spun down each time in a refrigerated centrifuge for 3—5 minutes at
40 750 r.p.m. After the blood was removed from the cells, they were diluted with 0.85% saline solution and counted in a hemocytometer. A final dilution of 2×10^7 cells/ml. in saline was made. Each animal received 0.2 ml. of
45 this suspension (4×10^6 cells/animals). This was injected intraperitoneally on day 0 of each test. Two groups (12 animals) were kept as negative controls, and the test was terminated at twice the mean day of death of the negative
50 controls. Two groups (12 animals) were the positive controls which were injected i.p. on day 1 with solution of *cis*-dichlorodiammineplatinum(II) in saline at a dose of 7 mg/kg. All test compounds were injected i.p. on day
55 one as a 0.5 ml. volume of the compound in a carrier of water, physiologic saline or arachis oil (peanut oil). Soluble compounds were always tested in appropriate solutions, the insoluble ones as a slurry. The slurry was sonicated for periods of up to 10 minutes to insure uniformity of dispersion just prior to injections. Generally, four dose levels, in a
60 doubling escalation, were tested for each compound. Retests were performed if a sufficient
65

level of drug toxicity at the highest dose was not reached. Animals still alive at the completion of the tests were considered to have died on the day of evaluation. Animals showing no abdominal distention (by palpation, or visibly) on this day were considered cured. Some cured animals later developed a solid tumor around the site of injection of the cells. This is believed to be due to a leakage of cells along the route of the needle on injection, or a later leak of cells through the injection hole in the peritoneum. In any case, this is considered an adventitious effect, which, when care is used in injections and smaller needles are used, become negligible.

The compounds tested were usually freshly prepared and purified. The compounds kept for further testing were stored in a vacuum desiccator in a dark refrigerator to prevent deterioration. In general, compounds of all classes tested had toxic levels at 200 mg/kg or greater. Toxic levels are considered to be that concentration where 2 or more of the 6 animals at the dose died within 8 days of injection. Animals dying after this time overlap with the early deaths of the negative controls.

For some of the complexes tested, the animals exhibited an excessive extension of the hind legs shortly after injection at high dose levels. The animals surviving the first two days, however, usually survived past the eight-day limit for toxic deaths. Some, however, did show an early death. Consistent with early

experience with platinum complexes, gross hepatic damage was minimal or non-existent (with the exceptions of $\text{Pt}(\text{CH}_3\text{CN})_2\text{Cl}_2$, the platinum-1-methyluracil and the platinum-5-bromo-1-methyluracil complexes. Peritonitis occurred in a similar number of cases at later times (day of evaluation, and up to 3 months later in cured animals). Symptoms of neuromuscular disorders were observed with a few compounds, shortly after high dose injections (i.e. platinum-uracil green precipitate). No symptoms of central nervous system disorders were ever observed in the test animals.

Unlike the solid Sarcoma-180, the ascites tumor in the Swiss White mice elicits no spontaneous regression (0/336), all tumored mice die, and the percent of no-takes is zero. The mean day of death is 17.5, with a small standard deviation (± 2.2 days).

The results of the survey tests are presented in Table 2. The letter A indicates the "blue" or first isolated precipitate, the letter B, the "green" or second precipitate. The data shown includes the carrier; the dose range tested; the toxic level (see above); the best percent increase in lifespan (% ILS), the maximum being 100% since the experiments were terminated at twice the mean life span of the negative controls; the dose level giving the best % ILS; the physical state of the inoculum (solution or slurry); and finally, the number of cured animals (out of 6 in each group).

35

40

45

50

55

60

65

TABLE 2
Survey Results of Antitumor Activity of Platinum Blue Complexes Against the Ascites Sarcoma 180 Tumor in Swiss White Mice

Compound	Carrier b	je	Toxic Level	Best % ILS	Dose of Best % ILS	Physical State c	# of cures d
negative control — average day of death = 17.5 (S.D. \pm 2.16)							
positive control <i>cis</i> -Pt(II)(NH ₃) ₂ Cl ₂	S	7	10	49 (S.D. \pm 2.82)	7	S	1 (of 12)
CLASS IA							
uracil	W	50-400	400	91	200	S	5
uracil	S	50-400	400	80	100	S	1
5,6-dihydrouracil	W	20-800	400	92	200	S	4
thymine	W	150-600	450	72	300	S	2
thymine	S	50-200	>200	67	150	S	1
5,6-dihydro-6-methyl uracil	W	50-400	200	89	50	S	2
6-methyluracil	S	200-800	>800	87	600	S	3
5,6-dimethyluracil	W	50-400	>400	100	400	S	5
5,6-dihydrothymine	S	50-400	400	87	200	S	2
1-methyluracil	S	50-400	>400	85	400	S	3
1-methylthymine	S	50-400	400	94	100	S	3
1-ethyluracil	S	50-400	200	38	50	S	0
5-fluorouracil	W	50-400	200	90	100	S	4
5-chlorouracil	W	50-400	200	67	50	S	3
6-chlorouracil	S	25-200	>200	88	200	S	3
5-bromo-1-methyluracil	S	50-400	>400	88	200	S	1

TABLE 2 (Continued)

Compound	Carrier	Range	Toxic Level	Best % ILS	Dose of Best % ILS	Physical State	# of cures
CLASS IA (Continued)							
5-iodouracil	P.O.	25-600	500	8	250	SI	0
5-hydroxymethyluracil	S	50-400	200	98	100	S	2
5-carbomethoxyuracil	S	25-200	200	56	200	S	0
6-carbomethoxyuracil	S	25-200	>200	38	25	S	0
uridine deoxyribose	S	25-200	>200	46	200	S	0
thymidine	S	50-400	200	46	50	S	1
5-iodouridine deoxyribose	P.O.	50-200	>200	23	200	SI	0
2',3',5'-triacyluridine	S	50-1000	800	79	600	S	2
2',3',5'-tribenzoyluridine	S	50-400	>400	19	100 & 200	S	0
2',3'-isopropylideneuridine	S	50-400	400	61	50	S	2
CLASS IB							
uracil	W	25-675	500	95	340	S	4
thymine	S	50-400	>400	60	200	S	0
1-methylthymine (yellow)	S	50-400	400	-14	100	S	0
1-ethyluracil	S	50-400	100	15	50	SI	0
5-fluorouracil	S	25-200	>200	37	200	S	0
MISC.							
Pt(CH ₃ CN) ₂ Cl ₂	S	6.3-50	50	83	25	S	1

* - Prepared by hydrolysis of Pt(CH₃CN)₂Cl₂

b - W = water, S = saline, P.O. = peanut oil.

c - S = solution, SI = slurry.

d - 6 animals per test, cures are considered as having no distention of abdominal cavity but do include formation of solid tumors at site of injection in some cases.

The results in Table 2 were obtained using Table 3. The *cis*-dichlorodiammineplatin- a single i.p. injection on day 1. Since this num(II) given as 8 injections of 1 mg/kg may not be the best schedule for treatment, each every 3 hours for the first day showed a samples of the drugs were selected for schedule surprisingly improved result over the single dependency tests. These are described in injection of 7 mg/kg (positive control).

10

TABLE 3

Results of Schedule Dependency Tests of Antitumor Activity of Selected Platinum Blue Complexes

Compound	Frequency of Injections	Number of Injections	Carrier ^b	Range	Toxic Level	Best % ILS	Dose of Best % ILS	Physical ^c State	# of cures
Negative Control — Average Day of Death 19.3 (S.D. ± 3.2)									
Positive Control <i>cis</i> -PT(II)(NH ₃) ₂ Cl ₂	day 1	1	S	7	10	42(S.D. ± 3.1)	7	S	1
<i>cis</i> -Pt(II)(NH ₃) ₂ Cl ₂	every 3 hrs.	8	S	1	1	86	1	S	5
	every day	5	S	3	3	19*	3	S	3
	every 5th day	5	S	5	5	83	5	S	3
	every 3 hrs.	8	S	50-125	100	80	50	S	1
Uracyl Class IA	every day	5	S	50-150	>150	100	100	S	6
	every 5th day	5	S	75-300	>300	100	150	S	3
	every 3 hrs.	4	S	100-250	>250**	73	100	S	3
	every day	5	S	25-200	200	68	100	S	5
Uracyl Class IB	every 5th day	5	S	100-400	400	84	200	S	5
	every 3 hrs.	8	S	50-200	200**	77	100	S	4
	every day	5	S	50-150	150**	91	50	S	5
	every 5th day	5	S	75-300	300	100	150	S	5

* Three animals died within 9 days of start — remainder cured.

** Number of injections varied because of severe animal response. Therefore, toxicity probably would have been reached had all animals received the same number of injections.

b — S = saline. c — S = solution, SI = slurry.

d — 6 animals per test, cures are considered as having no distention of abdominal cavity but do include formation of solid tumors at site of injection in some cases.

Tables 4—7, respectively, tabulate the results achieved when employing the complexes of the invention against the L1210, MCDV 12 (Rauscher Leukemia, virus induced), Ehrlich Ascites and the ADJ PC6A (myeloma) tumors. 5

TABLE 4

Effects of 'Platinum Blue' Complexes on the L1210 Tumor in BDF Mice ^a

Compound	Dose and Schedule		% ILS	Survivors
uracil Class IA	50	mg/kg qid x 5	16	0/3
	100	" " "	26	0/3
	61.25	" q3 hr x 8	30	0/3
	30.63	" " "	0	0/3
	250	" x 1	27	0/3
	500	" "	-58	0/3
thymine Class IA	100	mg/kg qid x 5	25	0/3
	30.63	" q3 hr x 8	32	0/3
	61.25	" " "	32	0/3
5,6-dihydrothymine Class IA	50	mg/kg qid x 5	36	0/3
	100	" " "	45	0/3
	30.63	" q3 hr x 8	30	0/3
	61.25	" " "	0	0/3
1-methyluracil Class IA	50	mg/kg qid x 5	10	0/3
	100	" " "	28	0/3
	30.63	" q3 hr x 8	10	0/3
	61.25	" " "	22	0/3

a) All experiments were terminated arbitrarily at 200% ILS and any survivors were tabulated at that time.

All therapy was started on the third day after tumor transplant.

Untreated tumor controls died 10 — 11 days after transplant.

In some instances efforts to reproduce above results have shown considerable variability.

TABLE 5

Effects of *cis*-Dichlorodiammin platinum (II) and 'Platinum Blues' on MCDV 12
(Rauscher Leukemia, Virus Induced) in BALB.C Mice ^a

Compound	Dose and Schedule	% ILS	Survivors
<i>cis</i> -Dichlorodiammine-platinum (II)	5 mg/kg × 1	146	2/3
	8 " "	62	0/2
	16 " "	-15	0/3
uracil Class IA	50 mg/kg qid × 5	200	3/3
	100 " " "	166	2/3
	25 " " "	85	1/3
	125 " × 1	107	1/3
	61.25 " q3 hr × 5	137	1/3
	30.63 " " × 8	37	0/3
	250 " × 1	-10	0/3
	500 " "	-60	0/3
thymine Class IA	100 mg/kg qid × 5	124	1/3
	30.63 " q3 hr × 7	156	2/3
	61.25 " " "	103	1/3
5,6-dihydrothymine Class IA	50 mg/kg qid × 5	157	2/3
	100 " " "	0	0/3
	30.63 " q3 hr × 8	75	1/3
	61.25 " " × 6	121	2/3
1-methyluracil Class IA	50 mg/kg qid × 5	88	1/3
	100 " " "	19	0/3
	30.63 " q3 hr × 8	34	0/3
	61.25 " " "	110	1/3

a) All experiments were terminated arbitrarily at 200% ILS and survivors tabulated at that time.

All therapy was started on third day after tumor transplant.

Untreated tumor controls died 10 - 11 days after transplant.

In some instances, efforts to reproduce above results have shown considerable variability.

TABLE 6

Effects of cis-Dichlorodiammineplatinum (II) and 'Platinum-Uracil Blue' on Survival Times of Mice Bearing the Ehrlich Ascites Tumor ^a

Compound	Dose (mg kg)	Mean Survival Time days (\pm S.D.)	% Increase in Mean Survival Time
Control	—	8.3 \pm 1.8	—
cis-Dichlorodiammineplatinum (II)	7	33.8 \pm 16.9	307 ^b
uracil Class IA	100	24.7 \pm 7.6	198
" "	200	25.2 \pm 7.4	204
" "	300	36.0 \pm 14.2	334
Control	—	10.1 \pm 2.8	—
cis-Dichlorodiammineplatinum (II)	7	29.7 \pm 4.2	194
uracil Class IA	200	25.7 \pm 4.5	154
" "	300	30.3 \pm 6.3	200
" "	400	28.5 \pm 4.2	182

a) 6 mice/group; each mouse received 10⁷ ascites tumor cells on day 0; treatment was as a single i. p. injection on day 1.

b) 2 animals in this group survived >60 days.

TABLE 7

Effects of cis-Dichlorodiammineplatinum (II) and 'Platinum Blues' on the ADJ/PC6A Tumor in Female, C⁻ Mice ^a

Compound	LD ₅₀	ID 90 (90% Inhibition)	Therapeutic Index
cis-dichlorodiammine-platinum (II)	13 mg. kg	1.6 mg/kg	8.1
uracil Class IA ^b	225 "	94 "	2.4
5,6-dihydrothymine Class IA	135 "	25 "	5.4
6-chlorouracil Class IA	200 "	190 "	1.05
5-carbethoxyuracil Class IA	670 "	250 "	2.7
1-methyluracil Class IA	670 "	50 "	13.4
5-hydroxymethyluracil Class IA	40 "	42 "	0.95

a) Injections, i.p. started 24 days after tumor implant, as single doses.

b) Injections, i.p. started 24 days after tumor implant, given daily for 5 days.

- Renal toxicity is the dose limiting side effect in higher animals and man under treatment with *cis*-dichlorodiammineplatinum(II). It is desirable to find other platinum drugs which cause much less severe renal toxicity. Described here are the results of histopathological examinations indicating that the "Platinum-Uracil Blue", Class IA, causes far less impairment of the kidneys than does *cis*-dichlorodiammineplatinum(II) or *cis*-dichloro(bis) cyclopentylamineplatinum(II), at roughly comparable therapeutic levels.
- The protocols for these tests were as follows: Each group contained six female Swiss White mice; the tumored animals were given a transplant of a solid Sarcoma-180 tumor on day 0 and treatment was initiated on day 1; the animals were sacrificed on day 10 and the kidneys removed and prepared for histological evaluation; control groups were non-tumored, non-treated animals, and tumored, non-treated animals. Multiple sections of each kidney were examined. Since *cis*-dichloro(bis)cyclopentylamineplatinum(II) is a very insoluble compound, and usually tested as a slurry in arachis oil, we felt it necessary to test it as saturated solutions in saline in order to be comparable with the other drugs. The saturation concentration cannot be specified other than an estimate of less than 1 mg/100 ml. A very brief summary of the results are compiled in Table 8. The histopathologic degenerative changes are dose dependent in all cases. While the higher dose levels of *cis* - dichlorodiammineplatinum (II) and *cis* - dichloro(bis)cyclopentylamineplatinum (II) caused generalized vacuolar (hydropic) degeneration of the proximal convoluted tubules, the higher doses of the "Platinum-Uracil Blue" Class IA, produced mild degenerative changes generally, with some severe, multiple small foci of necrosis.
- Since the function of a kidney containing foci of degenerative tissue should be less seriously impaired than kidneys in which entire anatomic/physiologic areas (i.e., proximal convoluted tubules) are involved, it is judged that the "Platinum-Uracil Blue" Class IA, is less nephrotoxic, (based upon renal histopathologic evidence) than the other two complexes, when compared at roughly equivalent therapeutic doses.
- 5
- 10
- 15
- 20
- 25
- 30
- 35
- 40
- 45
- 50

TABLE 8
Observed Renal Histopathological Changes in Mice Kidneys
[Limited to the proximal convoluted tubules]

1. cis-dichlorodiammineplatinum (II)		(Dosage Rate (mg/kg)				
Number of injections and time sequence between doses		0.5	1.0	2.0	3.0	7.0
8 (every 3 Hours)	normal	normal	normal	—	—	—
7 (every 24 hours)	—	—	normal	mild degenerative changes (cloudy swelling)	mild degenerative changes (cloudy swelling)	—
1 [tumored animal]	—	—	—	—	—	extensive degenerative changes (hydropic degeneration)
1 [non-tumored animal]	—	—	—	—	—	extensive degenerative changes (hydropic degeneration)

TABLE 8 (Continued)

2. uracil Class IA

Number of injections and time sequence between doses	Dosage Rate (mg/kg)			
	50	100	150	400
6 (every 3 hours)	—	—	focal areas of de- generation and necrosis. Hyaline casts also present.	—
8 (every 3 hours)	—	focal areas of de- generation and necrosis. Hyaline casts also present.	—	—
7 (every 24 hours)	mild congestion of renal cortex, otherwise normal.	extensive focal areas of degenerative change (hydropic degeneration)	isolated focal areas of degenerative change (hydropic degeneration)	—
1	—	—	—	mild degenerative changes (cloudy swelling) cortical hyperemia

TABLE 8 (Continued)

3. *cis*-dichloro(bis-cyclopentylamine)platinum (II)Number of injections and
time sequence between doses

Dosage Rate (mg./kg)

Saturated Solution

10
(every 3 hours)

normal

13
(every 3 hours)

normal

16
(every 3 hours)Mild to moderate degenerative changes.
Hydropic degeneration.20
(every 3 hours)Moderate generalized degenerative
changes. Hydropic degeneration.7
(every 24 hours)Mild generalized degenerative changes.
Cloudy swelling.

5 The following procedure was utilized to test the anti-microbial activity of the platinum complexes. The tests were performed with *Escherichia coli*-wild type, growing in test tube cultures. Using standardized techniques, growth in the medium was examined after the incorporation of the various test chemicals,

using the increase in the optical density of the medium as against time. The bacteria were also periodically examined under a phase contrast microscope for evidence of elongation (filamentation). The results of the tests are set forth in Table 9.

10

TABLE 9
Summary of Bacterial Studies with 'Platinum-Uracil Blues'

Optical Density of Bacterial Cultures

Compound	ppm	9:30 a.m.	10:45 a.m.	11:45 a.m. microscopic	12:45 p.m. microscopic	1:45 p.m. microscopic	2:45 p.m. microscopic
Control	0	.19	.32	.46 normal	.62 normal	.85 normal	.96 normal
<i>cis</i> -Pt(NH ₃) ₂ Cl ₂	7	.19	.31	.44 2× 50%	.62 2-4× 20%	.74 2-6× 40%	.78 2-6× 20%
<i>cis</i> -diaquodiammine-Pt(II)- 6-methyluracil	5	.16	.30	.43 normal	.54 normal	.77 normal	.90 normal
(prepared as in Ex. 1)	10	.18	.32	.45 normal	.72 normal	.90 normal	1.00 normal
	20	.18	.32	.45 normal	.74 normal	.96 normal	1.00 normal
	40	.17	.31	.42 normal	.68 < normal	.90 normal	.90 normal
<i>cis</i> -diaquodiammine-Pt(II)- uracil	5	.19	.25	.39 clumping	.64 clumping	.80 some clumping	.90 some clumping
(Ex. 1)	10	.21	.28	.41 clumping	.68 clumping	.85 clumping	1.00 clumping
	20	.23	.29	.40 clumping	.68 clumping	.90 clumping	.97 clumping
	40	.25	.30	.42 clumping	.53 clumping	.72 extreme clumping	.75 extreme clumping

TABLE 9 (Continued)

Compound	ppm	9:30 a.m.	11:00 a.m.	12:00 p.m. microscopic	1:00 p.m. microscopic	2:00 p.m.	3:20 p.m. microscopic
Control	0	.14	.29	.49 normal	.75 normal	.94	.95 normal
<i>cis</i> -Pt(NH ₃) ₂ Cl ₂	10	.12	.26	.37 2-4 × 60%	.49 2-8 × 60%	.55	.60 2-10 × 90%
<i>cis</i> -diaquodiammine-Pt(II)- 5,6-dihydrouracil (prepared as in Ex. 1)	5	.13	.24	.44 normal	.73 normal	1.00	1.00 normal
	10	.13	.23	.39 clumping	.72 clumping	.95	.95 normal
	20	.15	.26	.43 extreme clumping	.69 clumping	.81	1.00 some clumping
	40	.18	.27	.40 extreme clumping	.66 clumping	.82	1.00 some clumping
"Platinum-Acetamide Blue"	5	.19	.32	.48 normal	.78 normal	1.00	1.00 normal
	10	.27	.32	.32 normal	.32 < normal	.32	.31 < normal
	20	.33	.43	.41 tiny cells	.41 tiny cells	.41	.41 tiny cells
	40	.64	.95	.95 tiny cells	.81 tiny cells	.85	.85 tiny cells

The platinum complexes of the invention cause a clumping of the bacteria at fairly low concentrations. For example, the platinum-uracil complex causes clumping at levels of 5 ppm. Higher concentrations increase the clumping and result in eventual killing of the bacteria. The results would appear to indicate that the platinum complexes of the invention are potent anti-bacterial agents at low concentrations on the order of about 40 ppm.

The anti-viral activity of the platinum complexes of the invention was tested according to the following system. The system utilizes

the Fowl Pox Virus and the embryonated egg. In the first type, a known viral concentration is incubated with a known amount of a drug to be tested for various periods of time. The inoculum is then injected into the embryonated egg and on approximately day 10, the egg is opened, the chorioallantoic membrane removed, and the number of pock lesions counted. This type of test measures the *in vitro* inactivation of the Fowl Pox Virus by direct interaction with the new drug in a test tube. The second type of tests involves the inoculation of the embryonated egg with a

15

20

25

known titer of Fowl Pox Virus. At various times thereafter, a single dose of the compound to be tested is injected onto the chorio-allantoic membrane. Since after a period of a few hours the viral particles have disappeared and gone into the "eclipse phase" wherein the virion has been incorporated into the cell and begun its replication cycle, this test demonstrates the ability of the compound tested to enter into the cell and to disrupt the viral multiplication process. The results of these two types of tests are set forth in Tables 10 and 11.

TABLE 10

In Vitro Viral Inactivation of Fowl Pox Virus

with Platinum-Uracil^x Complex(6 × 10² μmg/ml of Pt.Uracil in incubation mixture)

Length of incubation (hrs.) prior to inoculation of mixture into embryonating eggs	Average number of pock lesions counted per egg	% Reduction ¹
0 Virus-Pt. Virus-H ₂ O	0 7.5	100%
1/6 Virus-Pt. Virus-H ₂ O	0.3 8.0	96.2%
1/2 Virus-Pt. Virus-H ₂ O	0.5 6.8	92.6%
1 Virus-Pt. Virus-H ₂ O	0 5.4	100%
2 Virus-Pt. Virus-H ₂ O	0.6 6.6	90.9%
4 Virus-Pt. Virus-H ₂ O	0.25 4.75	94.7%
6 Virus-Pt. Virus-H ₂ O	0.3 5.2	94.3%
8 Virus-Pt. Virus-H ₂ O	0 8.0	100%
26 Virus-Pt. Virus-H ₂ O	0 4.6	100%

¹per cent reduction = (1-Pt Blue/H₂O) × 100^xcis-diaquodiammine Pt (II)-Uracil (Ex. 1)

TABLE 11

In Vivo Anti-Viral Activity of Platinum-Uracil ^x

Complex Against Fowl Pox Virus

(0.36 mg Pt. Complex/egg

Elapsed time (hrs.) between inoculation of FPV onto chorio-allantoic membrane, and subsequent treatment with either Pt-Uracil complex or sterile distilled H ₂ O		Average number of pock lesions counted per egg.	% Reduction
0	Virus-Pt.	0	100%
	Virus-H ₂ O	6.75	
1/6	Virus-Pt.	1.25	78.3%
	Virus-H ₂ O	5.75	
1/2	Virus-Pt.	1.0	76.8%
	Virus-H ₂ O	4.3	
1	Virus-Pt.	0	100%
	Virus-H ₂ O	7.5	
2	Virus-Pt.	0.4	99.9%
	Virus-H ₂ O	6.8	
4	Virus-Pt.	1.6	79.5%
	Virus-H ₂ O	7.8	

^x *cis*-diaquodiammine Pt (II)-Uracil (Ex. 1)

5 For the tube inactivation tests, it was found that the virus is completely inactivated almost immediately upon exposure to the platinum-uracil complex. The inactivation of viable virions closely approaches 100%. This level remains at approximately 100% for up to 26 hours of incubation. This *in vitro* test demonstrates the extremely effective anti-viral activity

of the platinum complexes of the invention.

10 In Table 12, the *in vivo* inactivation results indicate that up to four hours after the viral inoculation, the platinum-uracil complex is still inhibiting the number of pock lesions to provide a 68% reduction in the number of 15 such lesions. A repetition of this test is given in Table 12.

TABLE 12

In Vivo Anti-Viral Activity of Platinum-Uracil^x

Complex Against F wl Pox Virus

(0.36 mg Pt. Blue/egg)


Elapsed time (hrs.) between inoculation of FPV onto chorio-allantoic membrane, and subsequent treatment with either Pt-Uracil complex or sterile distilled H ₂ O		Average number of pock lesions counted per egg	% Reduction
0	Virus-Pt	0.6	91.1
	Virus-H ₂ O	6.8	
1/6	Virus-Pt	0.7	90.4
	Virus-H ₂ O	7.0	
1/2	Virus-Pt.	1.0	88.1
	Virus-H ₂ O	8.4	
1	Virus-Pt	1.6	82.6
	Virus-H ₂ O	9.2	
2	Virus-Pt	2.5	69.5
	Virus-H ₂ O	8.2	
4	Virus-Pt	3.25	68.3
	Virus-H ₂ O	10.25	

^x *cis*-diaquodiammine Pt (II)-Uracil (Ex. 1)

Again, after four hours, approximately 80% reduction in the number of pock lesions is apparent after innoculation of the virus.

5 WHAT WE CLAIM IS:—

1. A platinum - [2,4 - dioxypyrimidine] complex prepared by reacting a 2, 4- dioxo-
pyrimidine having the formula:



10 wherein R₁ and R₂ may be the same or different and are selected from H, lower alkyl, di-lower alkyl amino, di-halo lower alkyl amino, halogen, hydroxy, hydroxy lower alkyl, and carboloweralkoxy,

15 R₃ and R₄ may be the same or different and are selected from H, lower alkyl ribosyl, deoxyribosyl, ribosyl, triacetyl-, tribenzoyl- or

2', 3' loweralkylidene ribosyl, ribosyl phosphates and deoxyribosyl phosphates, or a 5,6-dihydro derivative thereof

with *cis* - diaquodiammineplatinum (II) wherein the molar ratio of 2,4 - dioxopyrimidine to *cis* - diaquodiammineplatinum (II) is from 2:1 to 1:1 at a temperature of from 0 to 55°C., and for a time sufficient to form said complex.

2. A complex according to claim 1 wherein R₁, R₂, R₃ and R₄ are each H.

3. A complex according to claim 1 wherein R₁, R₄ and R₃ are each H and R₂ is CH₃.

4. A platinum - [2,4 - dioxopyrimidine] complex substantially as described in any one of the Examples.

5. A method of preparing a platinum-[2,4 - dioxopyrimidine] complex prepared by reacting a 2,4 - dioxopyrimidine having the formula (I), wherein R₁, R₂, R₃ and R₄ are as defined in any one of claims 1 to 3 with *cis* - diaquodiammineplatinum (II) wherein the molar ratio of 2,4 - dioxopyrimidine to *cis* - diaquodiammineplatinum (II) is from 2:1 to 1:1 at a temperature of from 0 to 55°C., and for a time sufficient to form

said complex and isolating said complex.

6. A method according to claim 5 wherein said reaction is conducted in an aqueous medium.
- 5 7. A method according to claim 6 wherein the pH of said aqueous medium is from 3 to 8.
8. A method according to any one of claims 5 to 7 wherein said temperature is room temperature.
- 10 9. A method according to any one of claims 5 to 8 wherein said reaction is conducted for from about 1 to about 21 days.
- 15 10. A method of preparing a platinum-[2,4 - dioxypyrimidine] complex substantially as described in any one of the Examples.
11. A platinum - [2,4 - dioxypyrimidine] complex prepared by a method according to any one of claims 6 to 10.
- 20 12. A composition adapted for intraperi-

toneal, intramuscular, subcutaneous or intravenous injection or per os administration to treat cancers, bacterial or viral infections comprising, in dosage unit form, a pharmaceutically acceptable carrier and from 0.1 mg/ml to 50 mg/ml of a complex according to any one of claims 1 to 4 and 11.

25

13. A method for the treatment of cancers, bacterial and viral infections, comprising the administration to a non-human living being afflicted therewith from 1 mg/kg to 800 mg/kg of body weight of a complex according to any one of claims 1 to 4 and 11.

30

HUSTWITT & CO.,
Chartered Patent Agents,
Ludgate House,
110 Fleet Street,
London, EC4A 2AB.

Printed for Her Majesty's Stationery Office by the Courier Press, Leamington Spa, 1977.
Published by the Patent Office, 25 Southampton Buildings, London, WC2A 1AY, from
which copies may be obtained.

1473148

COMPLETE SPECIFICATION

1 SHEET

*This drawing is a reproduction of
the Original on a reduced scale*

